OncoC4, Inc. has appointed Dr. Steve Chen, JD, PhD, as General Counsel, effective September 1, 2026. Founder, Chairman, and CEO Yang Liu, PhD, said Chen’s “combination of legal judgment, scientific training, and extensive biotechnology industry experience makes him an excellent addition to our leadership team,” adding that as OncoC4 “advances multiple clinical programs, expands its global operations, and collaborates with strategic partners, Steve will play an important role in supporting our corporate governance, intellectual property strategy, business development, compliance, and other legal matters.”
About Dr. Steve Chen
Chen said OncoC4 “has built an innovative pipeline grounded in deep scientific insight and has reached an important stage in its development,” and that he was “honored to join the company.” He pointed to AI-081, “rapidly advancing in global clinical development as a differentiated PD-1/VEGF bispecific antibody,” and ONC-841, “evaluated for its clinical potential in both oncology and neurodegenerative diseases,” saying he looks forward to “working with the leadership team to protect and expand OncoC4’s innovations.”
Chen brings nearly two decades of legal, intellectual property, corporate, and strategic experience in biotechnology and pharmaceuticals to the role. He most recently served as General Counsel of both HiFiBiO Therapeutics and ENSEM Therapeutics, handling corporate governance, intellectual property, financing, and regulatory matters. Before that, he held legal and intellectual property leadership roles at DSM and practiced law at Jones Day, focusing on life sciences patent matters. He began his career as a scientist at Vertex Pharmaceuticals before transitioning into law.
Chen holds a Ph.D. in biology and a J.D., and is a U.S.-licensed attorney and registered U.S. patent attorney.
About OncoC4
OncoC4 is a privately held, late clinical-stage biopharmaceutical company based in Rockville, Maryland, developing novel biologics for cancer and immunological diseases. Its pipeline includes AI-081 (cesalatamig), a wholly owned, differentiated bispecific antibody targeting PD-1 and VEGF in global clinical development; ONC-841, a first-in-class anti-SIGLEC-10 antibody in Phase 2 oncology and Phase 1 neurodegenerative disease trials; and gotistobart (BNT316/ONC-392), a tumor microenvironment-selective Treg depletion candidate targeting CTLA-4 co-developed with BioNTech.
